Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 8/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322779 | 0.82 | RAB9A (0.58) | RAB9AKMT2AALDH1A1L3MBTL1LMNA | |
| SCHEMBL4320360 | 0.80 | MEN1 (0.57) | RAB9AMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL4315412 | 0.80 | KMT2A (0.37) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4315423 | 0.80 | KMT2A (0.37) | RAB9AMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4312079 | 0.78 | CYP2D6 (0.47) | RAB9AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4308230 | 0.77 | KMT2A (0.43) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4314516 | 0.77 | MEN1 (0.43) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL10958150 | 0.76 | MEN1 (0.46) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL17727606 | 0.75 | CYP2D6 (0.54) | RAB9AKMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL4316505 | 0.74 | PTGDR2 (0.47) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | RAB9A 2711/4885MEN1 1830/4885KMT2A 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.